Inventiva's Stock Rises 4.34% at Close Following Fundraising

Stock Performance and Market Reaction

At the close of Thursday, November 20, Inventiva's stock settled at 3.61 euros, up 4.34% from the previous day's 3.46 euros. The stock fluctuated between 3.42 euros and 3.62 euros during the session, with moderate volumes representing 0.2% of the traded capital. This increase is part of a positive weekly trend of 7.92%, although the three-month performance remains negative at -5%. Over one year, however, the stock shows a remarkable performance of 38.85%, significantly outperforming the CAC 40, which only rose 10.39% over the same period. The Paris market closed up 0.34% at 7,981.07 points. This stock movement occurs in a particular financial context for the biopharmaceutical company. On November 17, Inventiva announced that the bookrunners of the public offering in the United States had fully exercised their option to subscribe to an additional 5,844,155 ADS, bringing the total amount of the operation to approximately $172.5 million. The subscription price was set at $3.85 per ADS, corresponding to 3.33 euros per ordinary share, with a discount of only 0.89% compared to the weighted average price. Technical analysis reveals a contrasting positioning of the stock. With an RSI at 52, the stock is in a neutral zone, confirming the absence of overbought or oversold signals. The MACD histogram shows a positive value of 0.06, suggesting a slight improvement in short-term dynamics, although the stock remains below its 50-day moving average positioned at 4.01 euros. The current price, however, is above the 200-day moving average (3.27 euros), indicating a positive long-term trend despite recent turbulence.

Strategic Importance of the Financing Operation

The financing operation is a major strategic element for the Dijon-based company. Inventiva plans to use the net proceeds from the offering mainly to fund the continuation of its phase 3 clinical trial, as well as the preparation of a confirmatory study and marketing activities. KBC Securities reiterated its 'buy' recommendation and price target of 8 euros, positively assessing this 108 million euro fundraising. This operation comes as the company had, as of September 30, 2025, cash reserves of 97.6 million euros according to the data provided. The recent history of the stock illustrates the characteristic volatility of biotechnological values in the clinical phase. The temporary suspension of trading on November 13, followed by the resumption of trading in the afternoon, marked the technical course of this capital increase. The one-month volatility stands at 22.79%, with a beta of 0.45 indicating relatively low sensitivity to overall market movements. The stock is currently fluctuating between a support identified at 3.04 euros and a resistance at 4.20 euros. Regarding governance, a recent purchase of 24,700 shares for approximately 81,379 euros by a manager demonstrates some confidence in the company's prospects. This transaction occurs in a context where the CMF (Chaikin Money Flow) displays a slightly positive value at 0.03, suggesting a moderately oriented cash flow towards the stock, without constituting a strong signal of accumulation.

Technical Indicators and Market Outlook

From a technical standpoint, the Bollinger Bands currently frame the price between 3.02 euros (lower bound) and 3.82 euros (upper bound), placing the current level of 3.61 euros in the upper part of this corridor. This position suggests some buying pressure without indicating immediate overheating. The ATR (Average True Range) at 0.11 confirms moderate daily volatility in absolute terms, while the negative OBV (On Balance Volume) at -53,705 reflects a distributive trend over the recent period, despite the rebound observed in recent days. The gap between the moving averages deserves special attention: with a 1.19 euro difference between the MM50 and the MM200 at the start of the analyzed period, this gap has gradually reduced to 0.77 euro currently, illustrating a convergence that could precede either stabilization or a new directional movement. The price is now 10.4% above its 200-day moving average, a favorable positioning in a medium-term perspective. The biopharmaceutical company, specializing in the development of lanifibranor for the treatment of MASH (metabolic dysfunction-associated steatohepatitis), continues its pivotal phase 3 clinical trial. The financial results for the third quarter are expected on November 21, which could provide additional elements on cash consumption and the progress of clinical programs. The stock is currently operating in an environment where investors seem to positively digest the securing of financial means, while remaining attentive to the next steps in clinical development.